Verastem Inc (NAS:VSTM) Stock News, Headlines & Updates
Verastem Inc Stock News from GuruFocus
- 1
- 2
Jul 11, 2025
Verastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock News
GuruFocus News • 3:46pm
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer
GuruFocus News • 3:32pm
Jul 08, 2025
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire • 7:00am
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VSTM Stock News
GuruFocus News • 6:48am
Jun 30, 2025
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade S
GuruFocus News • 3:19pm
Jun 25, 2025
Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News
GuruFocus News • 10:01am
RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News
GuruFocus News • 7:46am
Jun 24, 2025
Insider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)
GuruFocus News • 5:01pm
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
Business Wire • 4:00pm
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors | VSTM Stock News
GuruFocus News • 3:33pm
Verastem (VSTM) Begins Clinical Trials for Potential Cancer Treatment | VSTM Stock News
GuruFocus News • 3:16pm
Jun 02, 2025
Verastem (VSTM) Reports Promising Results in GFH375 Trial for Cancer Treatment | VSTM Stock News
GuruFocus News • 9:15am
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor | VSTM Stock News
GuruFocus News • 9:01am
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
Business Wire • 9:00am
May 28, 2025
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
Business Wire • 7:00am
Verastem Oncology to Present at the Jefferies Global Healthcare Conference | VSTM Stock News
GuruFocus News • 6:47am
May 22, 2025
Verastem (VSTM) Reports Promising Results in Metastatic Pancreatic Cancer Trial | VSTM Stock News
GuruFocus News • 4:30pm
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal A
GuruFocus News • 4:17pm
May 13, 2025
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Stock | VSTM Stock News
GuruFocus News • 4:15pm
Verastem (VSTM) Advances Pipeline with Key Developments | VSTM Stock News
GuruFocus News • 4:01pm
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
Business Wire • 4:00pm
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates | VSTM Stock News
GuruFocus News • 3:46pm
May 09, 2025
Verastem (VSTM) Sees Price Target Increase and FDA Approval Boost | VSTM Stock News
GuruFocus News • 9:02am
Verastem (VSTM) Stock Update: Analyst Raises Price Target to $14 | VSTM Stock News
GuruFocus News • 8:03am
Verastem (VSTM) Price Target Increased by RBC Capital Analyst | VSTM Stock News
GuruFocus News • 7:31am
Verastem (VSTM) Sees Increased Price Target Following FDA Approval | VSTM Stock News
GuruFocus News • 5:47am
May 08, 2025
Verastem (VSTM) Gains as Analyst Increases Price Target Following FDA Approval | VSTM Stock News
GuruFocus News • 1:15pm
FDA Approves the AVMAPKIâ„¢ FAKZYNJAâ„¢ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
Business Wire • 1:00pm
FDA Approves the AVMAPKIâ„¢ FAKZYNJAâ„¢ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer | VSTM Stock News
GuruFocus News • 12:30pm
FDA Greenlights Verastem's (VSTM) New Cancer Treatment
GuruFocus News • 12:01pm
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo | VSTM Stock News
GuruFocus News • 11:00am
May 01, 2025
Verastem (VSTM) Schedules Conference Call with Key Executives | VSTM Stock News
GuruFocus News • 10:45am
Verastem Oncology to Present at Upcoming Investor Conferences
Business Wire • 7:00am
Verastem Oncology to Present at Upcoming Investor Conferences | VSTM Stock News
GuruFocus News • 6:50am
BlackRock, Inc. Expands Stake in Verastem Inc. with Recent Acquisition
GuruFocus News • 8:44pm
Apr 25, 2025
Verastem Oncology Announces $75 million Private Placement
Business Wire • 9:00am
Verastem Oncology Announces $75 million Private Placement | VSTM Stock News
GuruFocus News • 8:18am
Apr 23, 2025
Verastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375
GuruFocus News • 4:56pm
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
Business Wire • 4:00pm
Verastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA Approval | VSTM Stock News
GuruFocus News • 3:37pm
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news